We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+19.43%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$676M
AUM Growth
-$147M
Cap. Flow
-$211M
Cap. Flow %
-31.23%
Top 10 Hldgs %
56.25%
Holding
63
New
9
Increased
11
Reduced
18
Closed
18

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$17M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$6.02M
3
ZBH icon
Zimmer Biomet
ZBH
+$5.83M
4
RGLS
Regulus Therapeutics
RGLS
+$4.5M
5
BAX icon
Baxter International
BAX
+$4.03M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$25.2M
2
HRTX icon
Heron Therapeutics
HRTX
+$15.1M
3
RXDX
Ignyta, Inc.
RXDX
+$14.9M
4
AERI
Aerie Pharmaceuticals
AERI
+$13.4M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
26
DELISTED
Cidara Therapeutics
CDTX
$6.64M 0.98%
41,020
+206
+0.5% +$29.3K
TTPH
27
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$6.16M 0.91%
+45,000
New +$6.02M
ZBH icon
28
Zimmer Biomet
ZBH
$17.3B
$5.74M 0.85%
+50,470
New +$5.83M
AMRN
29
Amarin Corp
AMRN
$285M
$5.71M 0.85%
81,622
-45,060
-36% -$3.19M
ACGN
30
DELISTED
Aceragen Inc
ACGN
$5.42M 0.8%
17,885
-10,474
-37% -$2.74M
RGLS
31
DELISTED
Regulus Therapeutics
RGLS
$5.37M 0.79%
+35,788
New +$4.5M
ZGNX
32
DELISTED
Zogenix, Inc.
ZGNX
$4.94M 0.73%
140,954
-121,546
-46% -$1.65M
NUVA
33
DELISTED
NuVasive, Inc.
NUVA
$4.88M 0.72%
88,000
+32,100
+57% +$2.12M
BAX icon
34
Baxter International
BAX
$11.2B
$4.1M 0.61%
+65,300
New +$4.03M
IART icon
35
Integra LifeSciences
IART
$1.44B
$3.96M 0.59%
+78,500
New +$4.03M
ACH
36
Accendra Health
ACH
$240M
$3.9M 0.58%
+133,700
New +$3.95M
AERI
37
DELISTED
Aerie Pharmaceuticals
AERI
$3.15M 0.47%
64,800
-245,200
-79% -$13.4M
CFRX
38
DELISTED
ContraFect Corporation
CFRX
$3.01M 0.45%
3,389
+1,732
+105% +$1.64M
MDWD icon
39
MediWound
MDWD
$183M
$2.67M 0.4%
71,429
+46,477
+186% +$2.05M
CGNT
40
DELISTED
Cogentix Medical, Inc.
CGNT
$2.57M 0.38%
1,004,352
-90,192
-8% -$198K
FOLD
41
DELISTED
Amicus Therapeutics
FOLD
$2.13M 0.31%
+141,000
New +$1.87M
TPST icon
42
Tempest Therapeutics
TPST
$15M
$781K 0.12%
188
+94
+100% +$402K
SSKN
43
DELISTED
Strata Skin Sciences
SSKN
$85K 0.01%
4,783
-1,878
-28% -$34.6K
ADMA icon
44
ADMA Biologics
ADMA
$1.94B
– –
-681,346
Closed -$2.52M
ATEC icon
45
Alphatec Holdings
ATEC
$1.26B
– –
-594,533
Closed -$1.1M
GILD icon
46
CALL
Gilead Sciences
GILD
$162B
– –
-180,000
Closed -$12.7M
CBIO
47
Crescent Biopharma
CBIO
$629M
– –
-2,218
Closed -$2.48M
GMED icon
48
Globus Medical
GMED
$10.2B
– –
-66,700
Closed -$2.21M
HRTX icon
49
CALL
Heron Therapeutics
HRTX
$86.9M
– –
-300,900
Closed -$4.17M
IRTC icon
50
iRhythm Holdings
IRTC
$3.54B
– –
-52,700
Closed -$2.24M
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Broadfin Capital held 63 positions worth $676M, down 18% from $823M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Broadfin Capital withdrew a net $211M in Q3 2017, closing 18 positions and reducing 18 holdings. Its most notable exit was Novadaq Technologies Inc., an estimated $11.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 75% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in Tetraphase Pharmaceuticals, Inc. worth $6.16M.

  • Broadfin Capital's largest Q3 2017 buy was Tetraphase Pharmaceuticals, Inc.: 45,000 shares worth $6.16M.
  • Broadfin Capital added most to Endo International plc in Q3 2017, an estimated $17M increase.
  • Broadfin Capital's biggest Q3 2017 reduction was Travere Therapeutics, cutting an estimated $25.2M.
  • Broadfin Capital fully exited Novadaq Technologies Inc. in Q3 2017, selling an estimated $11.7M.
  • Broadfin Capital's ten largest holdings make up 56% of its $676M portfolio in Q3 2017.
  • Broadfin Capital opened 9 new positions and closed 18 in Q3 2017.
  • Broadfin Capital's portfolio value fell 18% quarter-over-quarter to $676M.

Based on Broadfin Capital's 13F filing for Q3 2017, filed 14 Nov 2017.